Antibodies directed to the mammalian EAG1 ion channel protein
View Patent ↗The present invention relates to a particularly advantageous antibody, antibody fragment or derivative thereof, which specifically binds to/interacts with at least one epitope of the extracellular or intracellular domain or the mammalian EAG1 ion channel and to nucleic acid molecules encoding these anti-EAG1 antibodies, antibody fragments or derivatives and to vectors comprising such nucleic acid molecules. The invention additionally relates to methods for the preparation of such anti-EAG1 antibodies, antibody fragments or derivatives thereof, pharmaceutical compositions comprising these antibodies, antibody fragments or derivatives, and methods of using the antibodies, antibody fragments or derivatives or the compositions for a variety of purposes, such as diagnosing disease, treating disease, assessing for the presence of EAG1-expressing cells, or blocking EAG1 function in cells.
1. An isolated antibody, antibody fragment or derivative thereof comprising light chain variable (V L ) region complimentarity determining regions 1, 2, and 3 (CDR1, CDR2, and CDR3), and heavy chain variable (V H ) region CDR1, CDR2, and CDR3, the CDRs being present in each of said variable chains in CDR1, CDR2, CDR3 order and having the amino acid sequences of SEQ ID NOs: 166, 167, 168, 169, 170, and 171, respectively, wherein the antibody, antibody fragment or derivative thereof specifically binds to at least one epitope of the extracellular or intracellular domain of the mammalian ether-a-go-go 1 (EAG1) ion channel and does not bind to the mammalian EAG2 channel.
2. The antibody according to claim 1 , wherein said antibody is a monoclonal antibody.
3. The antibody fragment or derivative thereof according to claim 1 , wherein said antibody fragment thereof is a Fab-fragment, a F(ab′) 2 -fragment, or a Fv-fragment, and wherein said antibody derivative thereof is a single-chain antibody, a chimeric antibody, a CDR-grafted antibody, a bivalent antibody-construct, a humanized antibody, a human antibody, a synthetic antibody, a multispecific antibody, a diabody, or a chemically-modified Fab-fragment, F(ab′) 2 -fragment, Fv-fragment, single-chain antibody, chimeric antibody, CDR-grafted antibody, bivalent antibody-construct, humanized antibody, human antibody, synthetic antibody, multispecific antibody, or diabody.
4. The antibody or antibody derivative thereof according to claim 1 , wherein said antibody or antibody derivative thereof comprises a light chain selected from the group consisting of SEQ ID NOs: 6, 10, 18, 26 and 30, and a heavy chain selected from the group consisting of SEQ ID NOs: 8, 12, 20, 28 and 32.
5. The antibody, antibody fragment or derivative thereof according to claim 1 , wherein said antibody, fragment or derivative thereof is coupled to a labeling group.
6. A pharmaceutical composition comprising the antibody, antibody fragment or derivative thereof as defined in any one of claims 1 , 2 , 3 , 4 , and 5 .
7. The pharmaceutical composition of claim 6 , further comprising at least one anti-neoplastic agent.
8. A diagnostic composition comprising the antibody, antibody fragment or derivative thereof as defined in any one of claims 1 , 2 , 3 , 4 , and 5 , and optionally, a pharmaceutically acceptable carrier.
9. A kit comprising the antibody, antibody fragment or derivative thereof of any one of claims 1 , 2 , 3 , 4 , and 5 .
10. A method of assessing for the presence of EAG1 expressing cells comprising contacting a cell or tissue suspected of carrying EAG1 on its surface with the antibody, antibody fragment, or derivative thereof of any of claims 1 , 2 , 3 , 4 or 5 .
11. A method of blocking EAG1 function comprising contacting cells or a tissue suspected of carrying EAG1 on their/its surface with the antibody, antibody fragment or derivative thereof of any one of claims 1 , 2 , 3 , 4 and 5 .
12. The method of claim 10 , wherein said contacting is performed in vitro.
13. The method of claim 10 , wherein said contacting is performed in vivo.
14. The method of claim 11 , wherein said contacting is performed in vitro.
15. The method of claim 11 , wherein said contacting is performed in vivo.